Skip to content
Menu

Canaccord Genuity Maintains Buy on Twist Bioscience, Lowers Price Target to $150

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $205 to $150.

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $205 to $150.

Read at benzinga.com